BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation

A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia research 2015-09
Hauptverfasser: Tsai, Yo-Ting, Lozanski, Gerard, Lehman, Amy, Sass, Ellen J, Hertlein, Erin, Salunke, Santosh B, Chen, Ching-Shih, Grever, Michael R, Byrd, John C, Lucas, David M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Leukemia research
container_volume
creator Tsai, Yo-Ting
Lozanski, Gerard
Lehman, Amy
Sass, Ellen J
Hertlein, Erin
Salunke, Santosh B
Chen, Ching-Shih
Grever, Michael R
Byrd, John C
Lucas, David M
description A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF and MEK alleviated the BRAF -induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF and MEK can be used to delay disease progression and occurrence of resistance.
doi_str_mv 10.1016/j.leukres.2015.08.017
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_26350141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>26350141</sourcerecordid><originalsourceid>FETCH-LOGICAL-p93t-7e6fed3009a7be5cdcba70cf7f644cfb6084c78b6539f36dc91237c290a5c7113</originalsourceid><addsrcrecordid>eNo1j9FKwzAYhYMgbk4fQckLtPv_pkmay3ZsKgwcMrwdaZKOzK4tTTvc21tQrw4c-L7DIeQJIUZAsTzFtRu_ehfiBJDHkMWA8obMMZMs4hnjM3IfwgkAuEJ1R2aJYBwwxTlxxUe-oZ8CYE19Y0fjAs2LVYHLXXSsr6bt-nZwvqHuu5sGgm8bqhtLbT8e6VT4MOjGuImlRWRcXQd68ZrmuwipNoO_6GFCHshtpevgHv9yQfab9X71Gm3fX95W-TbqFBsi6UTlLANQWpaOG2tKLcFUshJpaqpSQJYamZWCM1UxYY3ChEmTKNDcSES2IM-_2m4sz84eut6fdX89_N9lP3zQVt0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</title><source>Access via ScienceDirect (Elsevier)</source><creator>Tsai, Yo-Ting ; Lozanski, Gerard ; Lehman, Amy ; Sass, Ellen J ; Hertlein, Erin ; Salunke, Santosh B ; Chen, Ching-Shih ; Grever, Michael R ; Byrd, John C ; Lucas, David M</creator><creatorcontrib>Tsai, Yo-Ting ; Lozanski, Gerard ; Lehman, Amy ; Sass, Ellen J ; Hertlein, Erin ; Salunke, Santosh B ; Chen, Ching-Shih ; Grever, Michael R ; Byrd, John C ; Lucas, David M</creatorcontrib><description>A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF and MEK alleviated the BRAF -induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF and MEK can be used to delay disease progression and occurrence of resistance.</description><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2015.08.017</identifier><identifier>PMID: 26350141</identifier><language>eng</language><publisher>England</publisher><ispartof>Leukemia research, 2015-09</ispartof><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26350141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsai, Yo-Ting</creatorcontrib><creatorcontrib>Lozanski, Gerard</creatorcontrib><creatorcontrib>Lehman, Amy</creatorcontrib><creatorcontrib>Sass, Ellen J</creatorcontrib><creatorcontrib>Hertlein, Erin</creatorcontrib><creatorcontrib>Salunke, Santosh B</creatorcontrib><creatorcontrib>Chen, Ching-Shih</creatorcontrib><creatorcontrib>Grever, Michael R</creatorcontrib><creatorcontrib>Byrd, John C</creatorcontrib><creatorcontrib>Lucas, David M</creatorcontrib><title>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF and MEK alleviated the BRAF -induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF and MEK can be used to delay disease progression and occurrence of resistance.</description><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo1j9FKwzAYhYMgbk4fQckLtPv_pkmay3ZsKgwcMrwdaZKOzK4tTTvc21tQrw4c-L7DIeQJIUZAsTzFtRu_ehfiBJDHkMWA8obMMZMs4hnjM3IfwgkAuEJ1R2aJYBwwxTlxxUe-oZ8CYE19Y0fjAs2LVYHLXXSsr6bt-nZwvqHuu5sGgm8bqhtLbT8e6VT4MOjGuImlRWRcXQd68ZrmuwipNoO_6GFCHshtpevgHv9yQfab9X71Gm3fX95W-TbqFBsi6UTlLANQWpaOG2tKLcFUshJpaqpSQJYamZWCM1UxYY3ChEmTKNDcSES2IM-_2m4sz84eut6fdX89_N9lP3zQVt0</recordid><startdate>20150905</startdate><enddate>20150905</enddate><creator>Tsai, Yo-Ting</creator><creator>Lozanski, Gerard</creator><creator>Lehman, Amy</creator><creator>Sass, Ellen J</creator><creator>Hertlein, Erin</creator><creator>Salunke, Santosh B</creator><creator>Chen, Ching-Shih</creator><creator>Grever, Michael R</creator><creator>Byrd, John C</creator><creator>Lucas, David M</creator><scope>NPM</scope></search><sort><creationdate>20150905</creationdate><title>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</title><author>Tsai, Yo-Ting ; Lozanski, Gerard ; Lehman, Amy ; Sass, Ellen J ; Hertlein, Erin ; Salunke, Santosh B ; Chen, Ching-Shih ; Grever, Michael R ; Byrd, John C ; Lucas, David M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p93t-7e6fed3009a7be5cdcba70cf7f644cfb6084c78b6539f36dc91237c290a5c7113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsai, Yo-Ting</creatorcontrib><creatorcontrib>Lozanski, Gerard</creatorcontrib><creatorcontrib>Lehman, Amy</creatorcontrib><creatorcontrib>Sass, Ellen J</creatorcontrib><creatorcontrib>Hertlein, Erin</creatorcontrib><creatorcontrib>Salunke, Santosh B</creatorcontrib><creatorcontrib>Chen, Ching-Shih</creatorcontrib><creatorcontrib>Grever, Michael R</creatorcontrib><creatorcontrib>Byrd, John C</creatorcontrib><creatorcontrib>Lucas, David M</creatorcontrib><collection>PubMed</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsai, Yo-Ting</au><au>Lozanski, Gerard</au><au>Lehman, Amy</au><au>Sass, Ellen J</au><au>Hertlein, Erin</au><au>Salunke, Santosh B</au><au>Chen, Ching-Shih</au><au>Grever, Michael R</au><au>Byrd, John C</au><au>Lucas, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2015-09-05</date><risdate>2015</risdate><eissn>1873-5835</eissn><abstract>A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF and MEK alleviated the BRAF -induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF and MEK can be used to delay disease progression and occurrence of resistance.</abstract><cop>England</cop><pmid>26350141</pmid><doi>10.1016/j.leukres.2015.08.017</doi></addata></record>
fulltext fulltext
identifier EISSN: 1873-5835
ispartof Leukemia research, 2015-09
issn 1873-5835
language eng
recordid cdi_pubmed_primary_26350141
source Access via ScienceDirect (Elsevier)
title BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T11%3A25%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BRAF%20V600E%20induces%20ABCB1/P-glycoprotein%20expression%20and%20drug%20resistance%20in%20B-cells%20via%20AP-1%20activation&rft.jtitle=Leukemia%20research&rft.au=Tsai,%20Yo-Ting&rft.date=2015-09-05&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2015.08.017&rft_dat=%3Cpubmed%3E26350141%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26350141&rfr_iscdi=true